• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆源性与重组因子 IX 在乙型血友病患者中的药代动力学和药效学特性:一项前瞻性交叉研究。

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.

机构信息

Centre for Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, UK.

出版信息

J Thromb Haemost. 2014 Dec;12(12):2044-8. doi: 10.1111/jth.12756. Epub 2014 Nov 11.

DOI:10.1111/jth.12756
PMID:25315324
Abstract

BACKGROUND

Effective treatment of acute bleeding episodes in patients with hemophilia B relies on factor IX recovery, with higher levels being more desirable, whereas prevention of bleeds with a prophylactic regimen depends on the half-life of the product. Lower recovery values have been reported following administration of recombinant FIX (rFIX) than following administration of plasma-derived FIX (pdFIX).

OBJECTIVES

To compare the pharmacokinetic and pharmacodynamic properties of rFIX and pdFIX in patients with hemophilia B.

METHODS

A prospective crossover study of nine patients with moderate to severe hemophilia B was performed. Following a washout period, 50 U kg(-1) FIX was administered, and blood samples were taken as per protocol up to 48 h postinfusion. Paired data were analyzed with the Wilcoxon signed rank test.

RESULTS

Mean peak recovery at 10 min postinfusion was 62.14 IU dL(-1) with pdFIX and 52.7 IU dL(-1) with rFIX (P = 0.08). Mean half-life was 16.6 h with pdFIX and 17.5 h with rFIX (P = 0.55). Maximum peak thrombin generation (PTG) was 35.9 nm with pdFIX and 28.9 nm with rFIX (P = 0.21). Administration of rFIX resulted in early PTG, whereas administration of pdFIX resulted in slightly later and sustained PTG. At 48 h, PTG was similar with pdFIX (19.0 nm) and rFIX (19.4 nm) (P = 0.91).

CONCLUSIONS

Patients experienced better recovery with pdFIX than with rFIX. pdFIX and rFIX had similar half-lives. Maximum PTG was higher for pdFIX; however, this difference did not reach statistical significance. The clinical impact of the slightly increased, delayed and sustained PTG with pdFIX requires further investigation.

摘要

背景

乙型血友病患者急性出血发作的有效治疗依赖于凝血因子 IX 的恢复,水平越高越理想,而预防性治疗方案则取决于产品的半衰期。与血浆源性凝血因子 IX(pdFIX)相比,重组凝血因子 IX(rFIX)给药后恢复值较低。

目的

比较乙型血友病患者 rFIX 和 pdFIX 的药代动力学和药效动力学特性。

方法

对 9 名中重度乙型血友病患者进行前瞻性交叉研究。在洗脱期后,给予 50 U kg(-1)FIX,根据方案在输注后 48 小时内采血。采用 Wilcoxon 符号秩检验对配对数据进行分析。

结果

pdFIX 给药后 10 分钟平均峰值恢复为 62.14 IU dL(-1),rFIX 为 52.7 IU dL(-1)(P = 0.08)。pdFIX 的平均半衰期为 16.6 小时,rFIX 为 17.5 小时(P = 0.55)。pdFIX 的最大峰值凝血酶生成(PTG)为 35.9 nm,rFIX 为 28.9 nm(P = 0.21)。rFIX 给药后早期出现 PTG,而 pdFIX 给药后出现稍晚但持续的 PTG。在 48 小时时,pdFIX(19.0 nm)和 rFIX(19.4 nm)的 PTG 相似(P = 0.91)。

结论

与 rFIX 相比,pdFIX 可使患者获得更好的恢复。pdFIX 和 rFIX 的半衰期相似。pdFIX 的最大 PTG 较高;然而,这一差异没有达到统计学意义。pdFIX 稍高、延迟和持续的 PTG 的临床影响需要进一步研究。

相似文献

1
Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.血浆源性与重组因子 IX 在乙型血友病患者中的药代动力学和药效学特性:一项前瞻性交叉研究。
J Thromb Haemost. 2014 Dec;12(12):2044-8. doi: 10.1111/jth.12756. Epub 2014 Nov 11.
2
Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.人群药代动力学模型用于设定非活化凝血因子 IX 聚乙二醇(N9-GP)的剂量。
J Thromb Haemost. 2012 Nov;10(11):2305-12. doi: 10.1111/jth.12000.
3
A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.关于重组和血浆来源的因子 IX 之间药代动力学差异的评论及其对剂量的影响。
Haemophilia. 2011 Mar;17(2):179-84. doi: 10.1111/j.1365-2516.2010.02431.x. Epub 2011 Feb 7.
4
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.人重组凝血因子IX:对既往接受血浆源性凝血因子IX浓缩物治疗的B型血友病患者的安全性和有效性研究。
Blood. 2001 Dec 15;98(13):3600-6. doi: 10.1182/blood.v98.13.3600.
5
Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.重组人凝血因子IX:犬血友病B的替代疗法、预防措施及药代动力学
Blood. 1996 Oct 1;88(7):2603-10.
6
Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.通过凝血酶生成试验和因子IX活性监测B型血友病患者每周一次的重组因子IX预防治疗。
Int J Lab Hematol. 2017 Aug;39(4):359-368. doi: 10.1111/ijlh.12634. Epub 2017 Apr 13.
7
Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).从pdFIX(Immunine®)安全转换为rFIX(Bax326)。
Haemophilia. 2014 Sep;20(5):674-81. doi: 10.1111/hae.12444. Epub 2014 Apr 10.
8
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.血友病 B 患者手术时因子 IX 的群体药代动力学。
J Thromb Haemost. 2018 Nov;16(11):2196-2207. doi: 10.1111/jth.14292. Epub 2018 Oct 28.
9
Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.重组人凝血因子IX在台湾既往接受治疗的B型血友病患者中的药代动力学研究。
J Formos Med Assoc. 2007 Apr;106(4):281-7. doi: 10.1016/S0929-6646(09)60253-9.
10
Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.重组凝血因子IX:一期凝血试验与发色底物法检测结果的差异
Haemophilia. 2014 Nov;20(6):891-7. doi: 10.1111/hae.12449. Epub 2014 May 7.

引用本文的文献

1
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study.罕见病患者使用孤儿药:一项基于人群的队列研究。
Front Pharmacol. 2022 May 16;13:869842. doi: 10.3389/fphar.2022.869842. eCollection 2022.
2
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.利用药代动力学为血友病患者在凝血因子产品转换时定制预防方案:一项范围综述。
Res Pract Thromb Haemost. 2019 May 20;3(3):528-541. doi: 10.1002/rth2.12204. eCollection 2019 Jul.
3
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.
重组凝血因子IX每周一次预防性给药可提高B型血友病患者的依从性。
J Blood Med. 2016 Nov 30;7:275-282. doi: 10.2147/JBM.S84597. eCollection 2016.
4
New developments in the management of moderate-to-severe hemophilia B.中重度B型血友病治疗的新进展
J Blood Med. 2016 Apr 1;7:27-38. doi: 10.2147/JBM.S81520. eCollection 2016.
5
Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.评估血友病治疗产品的相关问题——疗效、经济学与伦理学的交叉点。
J Blood Med. 2015 Jun 15;6:185-95. doi: 10.2147/JBM.S79091. eCollection 2015.